Topic: transdermal drug delivery
UCB’s dual inhibitor recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.
Fe3 Medical is moving forward with its wearable patch that uses electrical current to deliver iron directly through the skin.
The round equips the drug delivery device specialist move its transdermal ibuprofen patch candidate into the clinic early next year.
The failure of the study to hit a single goal or show a dose response raises big doubts about the prospects of the drug.
Fe3 Medical has received at $3.5 million boost from the state of Texas as part of a Series B funding round. The round now totals $14.5 million.